$APRE
Aprea Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Doylestown, PA
APRE chart
What traders are saying about $APRE
Latest postsAprea Therapeutics, Inc. news
- Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
Barchart.com ·
- Aprea Therapeutics, Inc. Estimates – NASDAQ:APRE
TradingView ·
- Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Yahoo Finance ·
- Aprea Therapeutics to Present at October Conferences
Yahoo Finance ·
- Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Yahoo Finance ·
- Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Yahoo Finance ·
- Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Yahoo Finance ·
- Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Yahoo Finance ·
- Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Yahoo Finance ·
- Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Yahoo Finance ·
- Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls
Yahoo Finance ·
Aprea Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M |
| Diluted EPS | $-1.93 | $-2.35 | $-3.95 | $-67.99 |
| Total assets (year end) | $15.9M | $24.0M | $22.7M | $30.2M |
| Cash and equivalents (year end) | $14.6M | $22.8M | $21.6M | $28.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Aprea Therapeutics, Inc.
- Ticker
- APRE (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Doylestown, PA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1781983
Frequently asked questions
What exchange is Aprea Therapeutics, Inc. listed on?
Aprea Therapeutics, Inc. trades on the Nasdaq under the ticker symbol APRE.
What industry is Aprea Therapeutics, Inc. in?
Aprea Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Aprea Therapeutics, Inc. headquartered?
Aprea Therapeutics, Inc.'s business address on file with the SEC is in Doylestown, PA.
When does Aprea Therapeutics, Inc.'s fiscal year end?
Aprea Therapeutics, Inc.'s fiscal year ends on December 31.